Riociguat is a novel soluble guanylate cyclase stimulator approved for the treatment of pulmonary arterial hypertension (PAH). Despite its widespread use, there has been a lack of large-scale studies
Datová sada obsahuje přehled nežádoucích událostí (NU), jejich rozdělení podle zdravotnického zařízení nebo typu poskytovatele zdravotních služeb (ZZ/PZS) a roku, ve kterém k nežádoucí události došlo
1A single subject accounted for all severe AEs which appeared on the day of positive blood smear, and all of which decreased in severity within 24 hours of treatment.2Per episode (number of episodes/s
*Adverse events leading to study drug discontinuation: Immediate Switch: emergent to EFV/FTC/TDF—anxiety; insomnia; night sweatsDelayed Switch: emergent to ABC/3TC + EFV (baseline to Wk12)—depressionD
